The natural world is the most ancient and successful source of medicines. Sirenas developed Atlantis™, the company’s proprietary data mining and deep learning software platform, to rapidly reveal the therapeutic potential of nature’s previously hidden, privileged chemistry. We seek to deploy Atlantis™ in the discovery of transformative medicines for the greatest unmet disease needs across the globe.

THE TEAM

#
Eduardo Esquenazi, PhD Chief Executive Officer, Founder
#
Jake Beverage, PharmD Chief Operating Officer, Co-founder
#
Phil Baran, PhD Co-founder
#
Mary Haak – Frendscho, PhD Board Member
#
Bob More Board Member
#
Eduardo Esquenazi, PhD Board Member
#
Jake Beverage, PharmD Board Member
#
Phil Baran, PhD Board Member
#
Benjamin Cravatt, PhD Scientific Adviser
#
Terry Rosen, PhD Scientific Adviser
#
Pieter Dorrestein, PhD Scientific Adviser
#
Christopher Walsh, PhD Scientific Adviser
#
Jin-Quan Yu, PhD Scientific Adviser
#
Alan Ezekowitz, MBChB, DPhil Scientific Adviser
#
Doron Shabat, PhD Scientific Adviser
#
Bill Gerwick, PhD Scientific Adviser
#
Eduardo Esquenazi, PhD Leadership
#
Jake Beverage, PharmD Leadership
#
Phil Baran, PhD Leadership
#
Mary Wheeler, PhD MBA Chief Business Officer
#
Rich Schiavi Vice President of Technology
#
Steven Cohen, PhD Senior Director of Oncology

PLATFORM TECHNOLOGY

The company’s proprietary software platform, Atlantis™, allows for the first time, a rapid approach to uncover the therapeutic potential of nature’s chemistry.

Atlantis™ uses extensive big data mining and deep learning approaches to continuously interrogate the relationships between millions of natural small molecule metabolites and disease relevant biological models. Atlantis™ provides rapid insights into the therapeutic potential, chemical novelty and global distribution of each metabolite.

This unprecedented functionality enables the uncovering of therapeutic leads from a previously hidden, rich pool of privileged chemistry that can be leveraged to help tackle the greatest unmet disease needs across the globe.

Atlantis Platform Validation

The goal of the Atlantis Platform is to decrease by orders of magnitude the time to translate chemical diversity from the ocean into lead programs for serious diseases. Sirenas first applied our marine-inspired technology to the discovery of cytotoxic payloads for antibody drug conjugates (ADCs) with differentiated mechanisms of action, and validated the Atlantis Platform with the generation of four exciting payload leads in just one year.

Immune Modulation by Novel Small Molecules

In 2016, with our validated discovery engine and expanded expertise and capacity in biology, including a close collaboration with the California Institute for Biomedical Research, Sirenas initiated an ambitious effort to identify and validate small molecule immune modulators. Despite a crowded and competitive immuno-oncology field, there remains a need for novel small molecules that can be used in combination with checkpoint inhibitors and other approaches to cancer, and represents a tremendous opportunity for both impact and a reduction in treatment cost. Additionally, the capacity to modulate the human immune response in predictable ways with small molecules is an exceptional opportunity across many additional unmet medical needs, including neuroscience, infectious and auto-immune diseases.

Neglected Diseases

Sirenas is also working with the Bill & Melinda Gates Foundation to leverage the Atlantis platform to bring forth promising small molecule scaffolds for malaria and tuberculosis.

 

PARTNERSHIPS

Together we will discover novel nature-inspired medicines that will impact patients across the globe

Atlantis™

Interested in leveraging the Atlantis™ technology for your programs? Sirenas is actively seeking partnership opportunities with global pharmaceutical companies.

Programs Available for Partnering

Sirenas initiated an ambitious effort to identify and validate small molecule oncology therapeutic leads using its Atlantis™ technology. Immune modulatory programs available for early stage partnering include T Cell Activation, PD-L1, STING and CD40.

The following antibody drug conjugate (ADC) payload programs are available for partnering:

  • Proprietary microtubule inhibitor candidate with increased potency, enhanced physiochemical properties and improved efficacy over current payloads in the clinic.
  • Proprietary mitochondrial protein disruptors.

Exploration

Sirenas seeks to explore ecologically interesting, untapped marine environments through innovative partnership with ocean communities around the world.

If you would like to seek a partnership opportunity with Sirenas, contact tamara.schwent@sirenasmd.com

IN THE NEWS

What the world is buzzing about Sirenas

08.15.17

Sirenas establishes world leading Scientific Advisory Board. View press release.

08.08.17

Sirenas appoints industry leaders to its Board. View press release.

06.15.17

CEO and Founder Eduardo Esquenazi shares “The Secret Language of Life” at TEDxUCSD. Watch the full TED talk.

12.23.16

HATCH by San Diego Magazine captures the story of Founder and CEO Eduardo Esquenazi and how it shaped Sirenas. Read full article.

12.08.16

Founder and CEO Eduardo Esquenazi speaks with the Smithsonian about his journey and the path forward for Sirenas LLC. Read full interview.

10.26.16

Learn more about how Sirenas is meeting the challenges of natural product discovery in a feature by Fast Company’s Fast Co.Exist!

10.18.16

Sirenas and Calibr form a drug discovery collaboration. View press release.

10.17.16

Sirenas is a panel finalist for South by Southwest 2017! Alongside Fabien Cousteau, Sirenas CEO Eduardo Esquenazi will address “Racing Climate Change to Cure Neglected Diseases” – Read full panel description.

10.03.16

CEO Eduardo Esquenazi speaks with Xconomy about Sirenas’ key innovation. Learn more.

09.29.16

Sirenas is awarded a grant to identify nature-inspired drug leads for neglected diseases. View press release.

09.29.16

The San Diego Business Journal features Sirenas in the wake of grant announcement.  Read more.

08.17.16

On this week’s BioTech Nation, looking for new drugs … in the ocean. Dr. Eduardo Esquenazi, Founder and CEO of Sirenas LLC, talks about bioprospecting.  Listen to full podcast.

03.10.16

Eduardo Esquenazi, Ph.D., founder and CEO of Sirenas LLC, will be a featured keynote presenter for the 2016 Gordon Research Conference on Marine Natural Products. View press release.

02.09.16

Sirenas is listed as one of 12 San Diego Life Sciences Startups to Watch in 2016! Read full article.

06.28.13

Sirenas named SDVG Cool Company for 2013. View press release.

CONTACT US

We’d Like to Hear From You

While it’s sometimes difficult to track down our marine discovery team, you can always reach one of us here at our San Diego headquarters.

Sirenas
3550 General Atomics Court. Suite 02/211
San Diego, CA 92121
email: info@sirenasmd.com / ph 858-909-5685

Drop Us a Line

Are You Ready to Make a Difference in the World of Therapeutics?

Sirenas connects the chemical diversity of our oceans with world-class science and cutting-edge technology to efficiently yield breakthrough therapeutics. We are actively looking for talented individuals to join our innovative team.

Please send us an email at careers@sirenasmd.com to inquire about current career opportunities.

email careers@sirenasmd.com